Table 2.
Parameters of CWA-TT in PRP from healthy volunteers, patients with solid cancer, and patients with malignancy.
| 2nd DPT (seconds) |
2nd DPH (mm ABS) |
1st DPT-1 (seconds) |
1st DPH-1 (mm ABS) |
1st DPT-2 (seconds) |
1st DPH-2 (mm ABS) |
FFCT (seconds) |
FFCH (mm ABS) |
|
|---|---|---|---|---|---|---|---|---|
| Healthy volunteers (n = 18) |
37.4 (33.1–43.3) |
124 (110–180) |
45.4 (39.2–50.2) |
101 (82.5–120) |
134 (112–137) |
45.3 (40.0–62.1) |
127 (115–139) |
730 (700–842) |
| Thrombocytopenia (n = 12) |
35.6 (32.3–38.7) |
174 (98.6–219) |
43.9 (39.9–44.7) |
115 (73.6–140) |
188 *** (146–216) |
29.2 *** (26.6–34.4) |
153 * (131–198) |
763 (682–865) |
| Malignant diseases (n = 16) |
33.7 (30.1–38.5) |
268 ** (185–339) |
39.3 (34.7–43.0) |
154 *** (126–176) |
111 (104–129) |
82.2 *** (76.4–108) |
102 * (98.2–118) |
953 (813–1067) |
Data are shown as the median (25–75 percentile). ***, p < 0.001, **, p < 0.01; *, p < 0.05 compared with healthy volunteers. PRP, platelet-rich plasma; 2nd DPT, second derivative peak time; 2nd DPH, second derivative peak height; 1st DPT, first derivative peak time; 1st DPH, first derivative peak height, FFCT, fibrin formation curve time; FFCH, fibrin formation curve height; ABS, absorbance.